Blood Pressure Control Could Save Over 500,000 Lives a Year Across 20 Countries

Effective management of high blood pressure could prevent more than 518,000 deaths from cardiovascular disease every year across 20 countries, according to preliminary modeling research presented at the American Heart Association’s Hypertension Scientific Sessions 2026, held October 7-11 in Arlington, Virginia. The analysis, an oral presentation at the meeting, examined what would happen if the use of six evidence-based preventive healthcare services were expanded from current levels to match the performance of high-achieving health systems in the United States, where roughly 80 percent of eligible patients receive the recommended care. Among all the services studied, bringing high blood pressure under control emerged as the single most life-saving intervention, with the greatest gains concentrated in upper-middle-income and lower-middle-income countries.

High blood pressure, or hypertension, is the most prevalent and modifiable risk factor for cardiovascular disease, and it affects adults in every age group. When left untreated, elevated pressure inside the arteries inflicts progressive damage on the vascular system. The sustained mechanical stress can cause narrowing of the arteries and the formation of aneurysms, weakened bulges in vessel walls that risk rupture. Over time, hypertension also drives a cascade of cardiac complications, including coronary artery disease, heart failure, enlargement of the left ventricle as the heart works harder against elevated resistance, and metabolic syndrome. Under the American Heart Association’s 2025 Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults, the treatment goal for adults with hypertension is a blood pressure below 130/80 mm Hg, reflecting evidence that tighter control reduces the risk of death and of serious conditions such as heart failure, stroke and dementia.

The stakes of the new analysis are framed by the global burden of non-communicable diseases. These chronic conditions are responsible for roughly three out of every five deaths worldwide, and approximately 73 percent of those deaths occur in low- or middle-income countries. Cardiovascular disease accounts for more of these deaths than other chronic conditions such as diabetes, cancers and chronic respiratory illnesses. Because hypertension is both widespread and treatable with inexpensive lifestyle measures and medications, it represents an unusually large and addressable gap in preventive care, particularly in countries where health systems have limited resources for chronic disease management.

The study was a modeling analysis rather than a clinical trial. Researchers identified the 20 countries with the highest numbers of deaths from non-communicable diseases, all of which fell into the World Bank’s upper-middle-income or lower-middle-income categories; no low-income countries were included. For each country, they assembled age- and sex-specific data on eligibility for and use of preventive services, drawing on sources including the Global Burden of Disease network, the NCD Risk Factor Collaboration, the WHO STEPwise Approach to NCD Risk Factor Surveillance and the WHO Cancer Screening databases. Statistical models were then applied to estimate how many lives could be saved annually if six preventive services were raised to guideline-based targets: blood pressure control, statin therapy for high cholesterol when indicated, glucose control in people with diabetes, and screening for colon, breast and cervical cancers.

The treatment and screening targets were anchored in major clinical guidelines. Blood pressure control was defined as readings below 140/90 mm Hg, the threshold at which the American Heart Association’s 2025 guideline recommends initiating blood pressure medication, although the guideline’s recommended treated target is below 130/80 mm Hg. Statin eligibility followed the criteria in the American Heart Association/American College of Cardiology’s 2026 dyslipidemia guideline. Glucose control was defined as a hemoglobin A1c below 7.0 percent, in line with the American Diabetes Association’s guideline, and cancer screening followed the age- and sex-appropriate intervals recommended by the U.S. Preventive Services Task Force. The benchmark for adequate service delivery was set at approximately 80 percent of eligible patients, the level observed in high-performing U.S. health systems.

The results quantified a hierarchy of opportunity. Expanding hypertension control to the target level was projected to prevent 518,476 annual cardiovascular deaths, the largest effect of any preventive service. Increasing statin treatment when indicated ranked second, with an estimated 340,682 cardiovascular deaths averted each year, followed by glucose management in people with Type 1 or Type 2 diabetes, projected to prevent 309,520 annual cardiovascular deaths. Among cancer screening modalities, raising colon cancer screening to 80 percent could prevent an estimated 206,767 colon cancer-related deaths annually, with cervical and breast cancer screening following in order of lives saved. The blood pressure benefit was distributed almost evenly across income tiers, with 223,282 annual deaths preventable in upper-middle-income countries and 223,655 in lower-middle-income countries.

Beneath those projections lies a stark picture of current under-treatment. The modeling estimates found that only about one in five adults with hypertension in the 20 studied countries had their blood pressure controlled to below 140/90 mm Hg. Just 16 percent of individuals with high cholesterol levels were using statins, only 39 percent of people with Type 1 or Type 2 diabetes had blood sugar below optimal levels, and between 14 and 26 percent underwent routinely indicated cancer screenings. These figures indicate substantial gaps in the use of preventive healthcare services in every country examined, with lower-middle-income countries showing the largest opportunities for improvement, including low rates of hypertension control and cholesterol management and minimal use of cancer screening tests.

Scott Pilla, M.D., M.H.S., an associate professor of medicine at Johns Hopkins University School of Medicine in Baltimore and the study’s lead researcher, said the team analyzed existing data to assess whether expanding the use of preventive services for non-communicable diseases across the 20 countries could reduce cardiovascular death. He noted that expanding treatment of high blood pressure to more people prevented the most deaths, followed by broader use of statin medications for high cholesterol and managing blood sugar in people with Type 1 or Type 2 diabetes. While there were substantial gaps in the use of preventive services for these conditions in all countries, he observed that lower-middle-income countries had large opportunities for improvement.

Independent experts emphasized that the findings reinforce established evidence rather than introduce new clinical uncertainty. Daniel W. Jones, M.D., FAHA, chair of the writing committee for the American Heart Association’s 2025 hypertension guideline, who was not involved in the study, said the modeling offers important information on the potential global impact of high blood pressure and the opportunity, with treatment, to reduce deaths from hypertension-related conditions. He noted that previous research has confirmed that following the evidence-based recommendations in the latest guideline can reduce the risk of death from high blood pressure and of other serious conditions such as heart failure, stroke and dementia, adding that treating blood pressure to goal leads to both longer and healthier lives and should inspire clinicians and patients to give more attention to management through lifestyle measures and medication.

As with any modeling study, important limitations apply. Some of the countries included in the analysis had limited data on the use of preventive care services, which introduces uncertainty into the estimates. The study also does not offer specific strategies for how to improve the use of and access to preventive healthcare services, and the researchers suggest that future studies should explore approaches to bridge the gaps identified. It is also worth noting that the analysis is a research abstract presented at a scientific meeting; abstracts presented at American Heart Association scientific sessions are not peer-reviewed, and the findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal. The abstract is scheduled for publication in the Hypertension Scientific Sessions 2026 Supplement of the journal Hypertension. Even with those caveats, the scale of the projected benefit, more than half a million preventable cardiovascular deaths each year from blood pressure control alone, underscores how much of the global burden of chronic disease rests on services that already exist, are already recommended, and remain dramatically underused.

Subject of Research: Modeling the impact of expanded preventive cardiovascular care on deaths across 20 countries

Article Title: Managing high blood pressure could prevent >500K CVD deaths annually in 20 countries

Article References: Managing high blood pressure could prevent >500K CVD deaths annually in 20 countries. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: hypertension, cardiovascular disease, preventive care, statins, diabetes, cancer screening, global health, middle-income countries, blood pressure control, non-communicable diseases, American Heart Association, modeling study